| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-028 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于调整可转换公司债券转股价格的公告 一、关于"万孚转债"转股价格调整的依据 经中国证券监督管理委员会"证监许可[2020]1830 号"文同意注册的批复， 公司于 2020 年 9 月 1 日向不特定对象发行了 600 万张可转换公司债券，每张面 值 100 元，发行总额 6.00 亿元。经深交所同意，公司 6.00 亿元可转换公司债券 于 2020 年 9 月 23 日起在深交所挂牌交易，债券简称"万孚转债"，债券代码 "123064"。 根据广州万孚生物技术股份有限公司（以下简称"公司"）《向不特定对象发 行可转换公司债券募集说明书》，在公司可转换公司债券发行之后，当公司因送 红股、转增股本、增发新股或配股、派息等情况（不包括因可转换公司债券转股 增加的股本）使公司股份发生变化时，将相应进行转股价格的调整。具体调整办 法如下： 公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Guangzhou Wanfang Biological Technology Co., Ltd., indicating a recent stock price increase and a low rolling PE ratio compared to the industry average [1][2] - As of May 12, the company's stock closed at 21.7 yuan, up 3.33%, with a rolling PE ratio of 19.62, marking a 24-day low, and a total market capitalization of 10.447 billion yuan [1] - The medical device industry has an average PE ratio of 49.84, with a median of 36.59, positioning Wanfang Biological at the 45th rank within the industry [1][2] Group 2 - For Q1 2025, the company reported revenue of 800 million yuan, a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37%, with a gross profit margin of 66.67% [2] - The company specializes in the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and reproductive health testing, and drug abuse testing [1] - Wanfang Biological has received numerous accolades, including being recognized as a national high-tech enterprise and a national-level "green factory" as of January 2025 [1]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-025 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 1、本次股东大会无增加、变更提案的情况。 2、本次股东大会以现场投票和网络投票相结合的表决方式。 3、本次股东大会未涉及变更前次股东大会决议的情形。 4、中小投资者是指除上市公司董事、监事、高级管理人员以及单独或者合 计持有公司 5%以上股份的股东以外的其他股东。 2024 年度股东大会会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 一、股东大会的召开和出席情况 广州万孚生物技术股份有限公司（以下简称"公司"）2024 年度股东大会于 2025 年 5 月 9 日 14:00 在公司 D 座三楼会议室召开。会议通知已于 2025 年 4 月 9 日在中国证监会指定的信息披露网站公告。本次股东大会由公司董事会召 集，董事长王继华女士主持，公司全体董事、监事、高级管理人员、公司聘请 的见证律师等相关人士出席、列席了本次会议。 ...

本次回购注销部分限制性股票实施完毕后，公司注册资本将相应减少。根据 《中华人民共和国公司法》和《公司章程》的相关规定，公司特此通知债权人， 债权人自本公告披露之日起 45 日内，有权要求公司清偿债务或者提供相应担保。 公司债权人如要求公司清偿债务或提供相应担保的，应根据《中华人民共和 国公司法》等相关法律法规的规定，向公司提出书面要求，并附随有关证明文件。 | 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-025 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于注销回购股份减少注册资本暨通知债权人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 5 月 9 日，广州万孚生物技术股份有限公司（以下简称"公司"） 召开 2024 年度股东大会，审议通过了《关于调整 2024 年限制性股票激励计划 的回购价格及回购注销部分限制性股票的议案》，鉴于公司 2024 年限制性股票 激励计划部分激励对象已离职不满足激励对象资格，本激励计划首 ...

北京市君合（广州）律师事务所 关于 广州万孚生物技术股份有限公司 2024 年年度股东大会的 法律意见书 二零二五年五月 | 北京总部 | 电话: (86-10) 8519-1300 | 上海分所 | 电话: (86-21) 5298-5488 | 广州分所 | 电话: (86-20) 2805-9088 | | 深圳分所 | 电话: (86-755) 2939-5288 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 传真: (86-10) 8519-1350 | | 传真: (86-21) 5298-5492 | | 传真: (86-20) 2805-9099 | | | 传真: (86-755) 2939-5289 | | 杭州分所 | 电话: (86-571) 2689-8188 | 成都分所 | 电话: (86-28) 6739-8000 | 西安分所 | 电话: (86-29) 8550-9666 | | 青岛分所 | 电话: (86-532) 6869-5000 | | | 传真: (86-571) 2689-8199 ...

Group 1 - Company closed at 20.93 yuan on May 6, with a 1.65% increase and a rolling PE ratio of 18.92 times, resulting in a total market value of 10.076 billion yuan [1] - The average PE ratio for the medical device industry is 48.90 times, with a median of 36.41 times, placing the company at the 44th position in the industry ranking [1] - The company experienced a net outflow of 3.0741 million yuan in main funds on May 6, with a total outflow of 3.2506 million yuan over the past five days [1] Group 2 - For Q1 2025, the company reported an operating income of 800 million yuan, a year-on-year decrease of 7.06%, and a net profit of 189 million yuan, down 13.37% year-on-year, with a gross profit margin of 66.67% [2] - The company is recognized as a key high-tech enterprise under the National Torch Program and has received various certifications, including being one of the first domestic in vitro diagnostic reagent companies to pass FDA on-site audits [1] - The company specializes in the research, production, and marketing of rapid diagnostic reagents and related instruments, focusing on infectious disease testing, chronic disease testing, pregnancy and prenatal testing, and drug abuse testing [1]

| 证券代码：300482 | 证券简称：万孚生物 公告编号：2025-025 | | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | 广州万孚生物技术股份有限公司 关于公司向银行申请综合授信并为经销商融资提供担保的公告 本公司及其董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"或"万孚生物"）因开 展日常经营业务所需，提出了《关于公司向银行申请综合授信并为经销商融资 提供担保的议案》，该议案已经公司第五届董事会第九次会议和第五届监事会第 七次会议审议通过。公司于2025年4月9日在巨潮资讯网（www.cninfo.com.cn） 披露了《关于公司向银行申请综合授信并为经销商融资提供担保的公告》 （2025-012），现对上述公告中"参股公司其他股东担保情况"内容信息进行补 充,补充后具体内容如下（补充部分见楷体加粗字体）： 一、本次申请综合授信并为经销商融资提供担保的情况： 广州万孚生物技术股份有限公司（以下简称"公司"或"万孚生物"）因开 展日常经营业务所需，向中国工商银行股份有限公司 ...

万孚生物（300482）公告，2025年第一季度营收为8亿元，同比下降7.06%；净利润为1.89亿元，同比下 降13.37%。 ...

Financial Performance - The company's revenue for Q1 2025 was ¥800,275,782.51, a decrease of 7.06% compared to ¥861,092,255.54 in the same period last year[5] - Net profit attributable to shareholders was ¥189,135,410.14, down 13.37% from ¥218,334,248.48 year-on-year[5] - Basic earnings per share decreased by 20.41% to ¥0.39 from ¥0.49 in the same period last year[5] - Total operating revenue for the current period was ¥800,275,782.51, a decrease of 7.06% from ¥861,092,255.54 in the previous period[18] - Net profit for the current period was ¥190,072,222.04, a decline of 13.75% compared to ¥220,443,620.50 from the previous period[19] - Earnings per share (EPS) for the current period was ¥0.39, down from ¥0.49 in the previous period[20] Cash Flow - The net cash flow from operating activities was -¥148,787,719.58, a significant decline of 231.41% compared to ¥113,224,704.67 in the previous year[5] - Cash inflow from operating activities totaled ¥557,099,837.33, a decrease of 25.06% from ¥743,368,930.59 in the previous period[22] - The net cash flow from operating activities was -$148.79 million, a decrease from $113.22 million in the previous period[23] - The cash outflow for operating activities totaled $705.89 million, compared to $630.14 million previously[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,182,545,912.53, reflecting a slight increase of 0.39% from ¥7,154,652,043.13 at the end of the previous year[5] - Current assets totaled CNY 3,824,674,042.04, up from CNY 3,785,861,965.80 at the start of the period[14] - Total current liabilities decreased to CNY 661,546,113.92 from CNY 821,464,141.00, indicating a reduction of approximately 19.5%[15] - The company’s total liabilities decreased to CNY 1,239,504,273.17 from CNY 1,392,436,610.63, indicating a reduction of approximately 11%[15] - Total liabilities amounted to ¥1,342,322,632.33, a decrease from ¥1,504,364,037.54[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 42,296[11] - The company’s equity position remains strong, with significant holdings by major shareholders, including Li Wenmei at 20.32% and Wang Jihua at 10.30%[13] - Total equity attributable to shareholders of the parent company increased to ¥5,743,386,505.55 from ¥5,554,388,042.84[16] Changes in Financial Metrics - The weighted average return on equity was 3.35%, down from 4.50% in the previous year[5] - The company reported a significant increase in accounts receivable by 89.06%, reaching ¥27,575,749.01 due to increased sales revenue settled by notes[9] - The company experienced a 62.99% decrease in cash and cash equivalents, totaling ¥306,674,463.35, primarily due to investments in financial products[9] - The company recorded a 1217.59% increase in fair value gains, amounting to ¥11,431,121.13, attributed to the fair value changes of trading financial assets[9] Inventory and Other Assets - Inventory decreased to CNY 319,592,386.44 from CNY 359,555,274.55, representing a decline of about 11.1%[14] - The company’s non-current assets totaled CNY 3,357,871,870.49, down from CNY 3,368,790,077.33[15] Accounting and Audit - The company did not undergo an audit for the first quarter report[24] - The new accounting standards will be implemented starting in 2025, affecting the financial statements[24]

海外业务收入高速增长，商业化进展成绩亮眼 2024 年，公司海外实现收入11.03 亿元，同比增长43.23%。（1）慢病管理检测：海外收入实现同比快 速增长。公司持续深化"一带一路"沿线发展中国家的市场深耕，在中小型医疗机构领域形成差异化竞争 优势，扩大终端市场份额。（2）传染病检测：在发展中国家，公司聚焦传染病检测公卫市场，深化与 政府及国际卫生组织的合作，扩大在血源性传染病等领域的市场份额。在美国，呼吸道检测业务取得了 突破性进展，公司的新型冠状病毒、甲型流感病毒及乙型流感病毒三联检测试剂盒（POC 版）/三联家 庭检测试剂盒（OTC 版）产品获得美国FDA EUA 授权，并于2025年1 月获得美国FDA 510（k）许可。 此外，公司的新冠抗原检测产品（OTC版）于2024 年9 月获得美国FDA 510（k）许可。 事件：近日，公司发布2024 年年报：2024 年实现营业收入30.65 亿元，同比上涨10.85%，主要系国际 业务增长带动；归母净利润5.62 亿元，同比上涨15.18%；扣非归母净利润4.97 亿元，同比上涨 19.90%。 其中，2024 年第四季度营业收入8.83 亿元，同比 ...